Detection of t helper responses, but not of human papillomavirus-specific cytotoxic t lymphocyte responses, after peptide vaccination of patients with cervical carcinoma

Journal of Immunotherapy

Volumn 23, Issue 2, 2000, Pages 255-266

  Ressing, Maaike E ^a   van Driel, Willemien J ^a   Brandt, Remco M P ^a   Kenter, Gemma G ^a   de Jong, Joan H ^a   Bauknecht, Thomas ^b   Fleuren, Gert Jan ^b   Hoogerhout, Peter ^b   Offringa, Rienk ^b   Sette, Alessandro ^b   Celis, Esteban ^c   Grey, Howard ^c   Trimbos, Baptist J ^d   Kast, W Martin ^d   Melief, Cornelis J M ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Cervical carcinoma; Human papillomavirus; Immunocompetence; Peptide; Vaccination

Indexed keywords

CANCER VACCINE; EPITOPE; FREUND ADJUVANT; HLA A ANTIGEN; HLA DR ANTIGEN; ONCOPROTEIN; SYNTHETIC PEPTIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR IMMUNITY; UTERINE CERVIX CARCINOMA; VACCINATION; WART VIRUS;

ADULT; AGED; CANCER VACCINES; CARCINOMA; CELL LINE, TRANSFORMED; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; K562 CELLS; MALARIA VACCINES; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0034069385     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200003000-00010     Document Type: Article

References (52)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54:594-606.
2. Schorge JO, Molpus KL, Koelliker D, et al. Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol 1997; 66:31-5.
3. Larson DM, Copeland LJ, Stringer CA, et al. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988; 30:381-7.
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
5. Zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochem Biophys Acta 1996; 1288:F55-78.
6. Seedorf K, Oltersdorf T, Krämmer G, Röwekamp W. Identification of early proteins of the human papillomaviruses type 16 (HPV16) and type 18 (HPV18) in cervical carcinoma cells. EMBO J 1987; 6:139-44.
7. Von Knebel Doeberitz M, Bauknecht T, Bartsch D, Zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 1991; 88:1411-15.
8. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-9.
9. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, et al. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995; 25:2638-42.
10. De Bruijn MLH, Schuurhuis DS, Vierboom MPM, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998; 58:724-31.
11. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152:3904-12.
12. Imanishi I, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Oxford: Oxford University Press, 1992, pp 1065-1220.
13. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154:5934-43.
14. Ressing ME, Van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996; 56:582-8.
15. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57:2943-50.
16. Nimako M, Fiander AN, Wilkinson GWG, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 1997; 57:4855-61.
17. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 95:341-9.
18. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1:751-61.
19. Del Guercio MF, Alexander J, Kubo RT, et al. Potent immunogenic short linear peptide contructs composed of B cell epitopes and Pan DR T helper Epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15:441-8.
20. Claas ECJ, Melchers WJG, Van der Linden HC, Lindeman J, Quint WGV. Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol 1989; 135:703-9.
21. Ressing ME, De Jong JH, Brandt RMP, et al. Differential binding of viral peptides to HLA-A2 alleles. Implications for HPV16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol 1999; 29:1292-303.
22. Van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I/II trial. Eur J Cancer 1999; 35:946-52.
23. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996; 12:259-72.
24. Kono K, Ressing ME, Brandt RMP, et al. Decreased expression of signal transducing chain on peripheral T cells and NK cells in patients with cervical cancer. Clin Cancer Res 1996; 2:1825-8.
25. Nieland JD, Loviscek K, Kono K, et al. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR expression but are functionally impaired. J Immunother 1998; 21:317-22.
26. Anderson P, Caligiuri M, O'Brien C, et al. Fcg receptor type III (CD16) is included in NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci USA 1990; 87:2274-8.
27. Browning M, Krausa P. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 1996; 17:165-70.
28. Levey DL, Srivastava PK. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today 1996; 17:365-8.
29. Toes R, Ossendorp F, Offringa R, Melief C. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189:753-6.
30. Livingston BD, Crimi C, Grey H, et al. The Hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997; 159:1383-92.
31. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66:162-9.
32. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/ Melan-A. Cancer J Sci Am 1997; 3:37-44.
33. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-57.
34. Rosenberg SA, Yang YC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
35. Hu X, Chakraborty NG, Sporn JR, et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56:2479-83.
36. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.
37. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32.
38. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8.
39. Melief CJM, Offringa R, Toes REM, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol 1996; 8:651-7.
40. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based anti-tumor vaccines. Stem Cells 1997; 15:94-103.
41. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
42. Lee K, Panelli M, Kim C, et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161:4183-94.
43. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed. Papillomavirus Rep 1992; 3:123-26.
44. Connor ME, Stern PL. Loss of MHC class I expression in cervical carcinomas. Int J Cancer 1990; 46:1029-34.
45. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
46. Duggan-Keen M, Keating PJ, Cromme FV, Walboomers JMM, Stern PL. Alterations in major histocompatibility complex expression in cervical cancer: possible consequences for immunotherapy. In: Lacey, C. ed. Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press, 1996, 141-50.
47. Honma S, Tsukada S, Honda S, et al. Biological-clinical significance of selective loss of HLA class I allelic product expression in squamous cell carcinoma of the uterine cervix. Int J Cancer 1994; 57:650-5.
48. Wagner G. Hautteste als Immunparameter beim Zervixkarzinom. Wiener Klinische Wochenschrift 1984; 96:467-73.
49. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89:245-50.
50. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7.
51. Steller M, Gurski K, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4:2103-9.
52. Thomas GM. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. J Natl Cancer Inst Monogr 1996; 21:77-83.